Cite
HARVARD Citation
Kuruvilla, J. et al. (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet oncology. 22 (4), pp. 512-524. [Online].